Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
作者： Sean Tracy , Toru Mukohara , Mark Hansen , Matthew Meyerson , Bruce E. Johnson
DOI: 10.1158/0008-5472.CAN-04-1905
关键词: EGFR inhibitors 、 Epidermal growth factor receptor 、 Protein kinase B 、 Pathology 、 Cancer research 、 Adenocarcinoma 、 Lung cancer 、 Apoptosis 、 Tyrosine kinase 、 Gefitinib 、 Medicine
摘要: Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) have recently been described in patients with non–small-cell lung cancer (NSCLC) who …
aacrjournals.org
sci-hub.se 参考文章(21)
Mitsudomi T, Minna Jd, Gazdar Af, Mulshine Jl, Viallet J, Linnoila Ri, Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines Oncogene. ,vol. 6, pp. 1353- 1362 ,(1991)
Michele L Taffaro, Bruce E Johnson, Ravi Salgia, Pasi A Jänne, Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Research. ,vol. 62, pp. 5242- 5247 ,(2002)
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
Wenle Xia, Robert J Mullin, Barry R Keith, Lei-Hua Liu, Hong Ma, David W Rusnak, Gary Owens, Krystal J Alligood, Neil L Spector, Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene. ,vol. 21, pp. 6255- 6263 ,(2002) , 10.1038/SJ.ONC.1205794
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
John Mendelsohn, Jose Baselga, The EGF receptor family as targets for cancer therapy. Oncogene. ,vol. 19, pp. 6550- 6565 ,(2000) , 10.1038/SJ.ONC.1204082
P Harvey, A Warn, S Dobbin, N Arakaki, Y Daikuhara, MC Jaurand, RM Warn, Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology British Journal of Cancer. ,vol. 77, pp. 1052- 1059 ,(1998) , 10.1038/BJC.1998.176
Christopher Y. Thomas, Michael Chouinard, Michael Cox, Sarah Parsons, Melody Stallings-Mann, Roy Garcia, Richard Jove, Robert Wharen, Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells. International Journal of Cancer. ,vol. 104, pp. 19- 27 ,(2003) , 10.1002/IJC.10880
Renee Bailey, Mark Kris, Michael Wolf, Andrea Kay, Steven Averbuch, Jon Askaa, Mette Janas, Karsten Schmidt, Masahiro Fukuoka, O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone Lung Cancer. ,vol. 41, ,(2003) , 10.1016/S0169-5002(03)91900-3
Vincent A. Miller, Mark G. Kris, Neelam Shah, Jyoti Patel, Christopher Azzoli, Jorge Gomez, Lee M. Krug, William Pao, Naiyer Rizvi, Barbara Pizzo, Leslie Tyson, Ennapadam Venkatraman, Leah Ben-Porat, Natalie Memoli, Maureen Zakowski, Valerie Rusch, Robert T. Heelan, Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 22, pp. 1103- 1109 ,(2004) , 10.1200/JCO.2004.08.158